Claude is Senior Advisor at HealthTech180 and former Head of Global Market Access at ViiV and GlaxoSmithKline. He spent his entire career in HealthCare, mostly as a Rare Disease specialist.
Claude is highly analytical, having graduated with a MSc in Maths and Physics from Ecole Polytechnique (X) and possesses an outstanding attention to detail.
More recently he has worked as the Head of Global Market Access for ViiV Healthcare, driving the business to new heights through diligent market analysis and a comprehensive understanding of Global Markets. At GSK, he was involved in the Gene Therapy team for a number of rare diseases (Fabry disease, Duchenne muscular dystrophy and Amyloidosis). His team was the first to obtain reimbursement access for Strimvelis (the first commercially successful curative gene therapy).